Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)

NCT06820281 is registered in ClinicalTrials.gov with Victor Chang Cardiac Research Institute as lead sponsor.

NCT NCT06820281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06820281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)
Lead sponsor
Victor Chang Cardiac Research Institute
Phase
Phase 2
Overall status
Recruiting
Start date
July 7, 2026
Completion date
December 31, 2027
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus